1 Hall SD, Thummel KE,Watkins PB, Lown KS, Benet LZ, Paine MF, et al.Molecular and physical mechanisms of first-pass extraction[J]. Drug Metab Dispos, 1999;27: 161-6 2 Hsing S, Gatmaitan Z, Arias IM.The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa[J]. Gastroenterology, 1992; 102:879-85 3 Fromm MF.The influence ofMDR1 polymorphisms on P-gly coprotein expression and function in humans[J]. Adv Drug Deliv Rev, 2002;54: 1295-310 4 Marzolini C, Paus E, Buclin T, Kim RB.Polymorphisms in human MDR1 (P-glycoprotein):recent advances and clinical relevance[J]. Clin Pharmacol Ther, 2004;75: 13-33 5 Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ.Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery[J]. J Control Release, 1999;62: 25-31 6 von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT.Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes:a comparative analysis in paired tissue specimens[J]. Clin Pharmacol Ther, 2004; 75:172-83 7 Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al.Differentiation of absorption and first-pass gut and hepatic metabolism in humans:studies with cyclosporine[J]. Clin Pharmacol Ther, 1995;58:492-7 8 Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al.Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression[J]. J Clin Invest, 1997;99:2545-53 9 Thummel KE, O' Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al.Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism[J]. Clin Pharmacol Ther, 1996; 59:491-502 10 von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, et al.Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique[J]. Clin Pharmacol Ther, 2001;70:217-27 11 Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al.Role of intestinal P-glycoprotein (mdr1)in interpatient variation in the oral bioavailability of cyclosporine[J]. Clin Pharmacol Ther, 1997;62: 248-60 12 Kato M, Chiba K, Hisaka A, IshigamiM, Kay ama M, Mizuno N, et al.The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature[J]. Drug Metab Pharmacokinet, 2003; 18:365-72 13 Lin JH, Chiba M, Baillie TA.Is the role of the small intestine in first-pass metabolism overemphasized[J]. Pharmacol Rev, 1999; 51:135-58 14 Schwab M, Eichelbaum M, Fromm MF.Genetic polymorphisms of the human MDR1 drug transporter[J]. Annu Rev Pharmacol Toxicol, 2003;43:285-307 15 Fromm MF.Importance of P-glycoprotein for drug disposition in humans[J]. Eur J Clin Invest, 2003;33:6-9 16 Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al.The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors[J]. J Clin Invest, 1998;101: 289-94 17 Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al.Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene[J]. Clin Pharmacol Ther, 2002;72:584-94 18 Masuda S, Goto M, Kiuchi T, Uemoto S, Kodawara T, Saito H, et al.Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation[J]. Liver Transpl, 2003; 9:1108-13 19 Masuda S, Goto M, Okuda M, Ogura Y, Oike F, Kiuchi T, et al. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients[J]. Transplant Proc, 2005;10(7);37: 1728-9 20 Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients[J]. Clin Pharmacol Ther, 2004;75: 352-61 21 Asano T, Nishimoto K, Hayakawa M.Increased tacrolimus trough levels in association with severe diarrhea, a case report[J]. Transplant Proc, 2004; 36:2096-7 22 Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y.Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea[J]. Am J Transplant, 2005;5: 1383-91 23 Wille RT, Lown KS, Huszczo UR, Schmiedlin-Ren P, Watkins PB.Short term effect of medications on CYP3A4 and P-gly coprotein expression in human intestinal mucosa[J]. Gastroenterology, 1997; 112:A419 24 Fromm MF.Importance of P-glycoprotein at blood-tissue barriers[J]. Trends Pharmacol Sci, 2004; 25:423-9 25 Zhang Y, Benet LZ.The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein[J]. Clin Pharmacokinet, 2001;40: 159-68 26 Hochman JH, Chiba M, Yamazaki M, Tang C, Lin JH.Pgly coprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4[J]. J Pharmacol Exp Ther, 2001; 298: 323-30 27 Cummins CL, JacobsenW, Benet LZ.Unmasking the dynamic interplay between intestinal P-gly coprotein and CYP3A4[J]. J Pharmacol Exp Ther, 2002;300:1036-45 28 Chan LM, Cooper AE, Dudley AL, Ford D, Hirst BH.P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification[J]. J Drug Target, 2004;12: 405-13 29 Johnson BM, CharmanWN, Porter CJ.The impact of P-gly coprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil[J]. J Pharm Pharmacol, 2001;53: 1611-9 30 Mouly SJ, Paine MF, Watkins PB.Contributions of CYP3A4, P-gly coprotein, and serum protein binding to the intestinal firstpass extraction of saquinavir[J]. J Pharmacol Exp Ther, 2004; 308:941-8 31 Paine MF, Leung LY, Watkins PB.New insights into drug absorption: studies with sirolimus[J]. Ther Drug Monit, 2004; 26:463-7 32 Cummins CL, Salphati L, ReidMJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model[J]. J Pharmacol Exp Ther, 2003; 305: 306-14 33 Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF.P-glycoprotein-mediated intestinal and biliary digoxin transport in humans[J]. Clin Pharmacol Ther, 2003;73: 223-31 34 Kharasch ED, Walker A, Hoffer C, Sheffels P.Evaluation of first-pass cytochrome P4503A(CYP3A)and P-glycoprotein activities using alfentanil and fexofenadine in combination[J]. J Clin Pharmacol, 2005; 45:79-88 35 Lau YY, Wu CY, Okochi H, Benet LZ.Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay[J]. J Pharmacol Exp Ther, 2004;308:1040-5 |